Literature DB >> 25200955

Ligation of TLR5 promotes myeloid cell infiltration and differentiation into mature osteoclasts in rheumatoid arthritis and experimental arthritis.

Seung-Jae Kim1, Zhenlong Chen1, Nathan D Chamberlain1, Abdul B Essani1, Michael V Volin2, M Asif Amin3, Suncica Volkov1, Ellen M Gravallese4, Shiva Arami1, William Swedler1, Nancy E Lane5, Anjali Mehta1, Nadera Sweiss1, Shiva Shahrara6.   

Abstract

Our aim was to examine the impact of TLR5 ligation in rheumatoid arthritis (RA) and experimental arthritis pathology. Studies were conducted to investigate the role of TLR5 ligation on RA and mouse myeloid cell chemotaxis or osteoclast formation, and in addition, to uncover the significance of TNF-α function in TLR5-mediated pathogenesis. Next, the in vivo mechanism of action was determined in collagen-induced arthritis (CIA) and local joint TLR5 ligation models. Last, to evaluate the importance of TLR5 function in RA, we used anti-TLR5 Ab therapy in CIA mice. We show that TLR5 agonist, flagellin, can promote monocyte infiltration and osteoclast maturation directly through myeloid TLR5 ligation and indirectly via TNF-α production from RA and mouse cells. These two identified TLR5 functions are potentiated by TNF-α, because inhibition of both pathways can more strongly impair RA synovial fluid-driven monocyte migration and osteoclast differentiation compared with each factor alone. In preclinical studies, flagellin postonset treatment in CIA and local TLR5 ligation in vivo provoke homing and osteoclastic development of myeloid cells, which are associated with the TNF-α cascade. Conversely, CIA joint inflammation and bone erosion are alleviated when TLR5 function is blocked. We found that TLR5 and TNF-α pathways are interconnected, because TNF-α is produced by TLR5 ligation in RA myeloid cells, and anti-TNF-α therapy can markedly suppress TLR5 expression in RA monocytes. Our novel findings demonstrate that a direct and an indirect mechanism are involved in TLR5-driven RA inflammation and bone destruction.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25200955      PMCID: PMC4185216          DOI: 10.4049/jimmunol.1302998

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  56 in total

1.  TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL.

Authors:  Karen Fuller; Chiho Murphy; Barrie Kirstein; Simon W Fox; Timothy J Chambers
Journal:  Endocrinology       Date:  2002-03       Impact factor: 4.736

2.  TLR5, a novel and unidentified inflammatory mediator in rheumatoid arthritis that correlates with disease activity score and joint TNF-α levels.

Authors:  Nathan D Chamberlain; Olga M Vila; Michael V Volin; Suncica Volkov; Richard M Pope; William Swedler; Arthur M Mandelin; Shiva Shahrara
Journal:  J Immunol       Date:  2012-06-01       Impact factor: 5.422

Review 3.  Endogenous ligands of Toll-like receptors.

Authors:  Min-Fu Tsan; Baochong Gao
Journal:  J Leukoc Biol       Date:  2004-06-03       Impact factor: 4.962

Review 4.  The role of Toll-like receptor signalling in the pathogenesis of arthritis.

Authors:  Fabia Brentano; Diego Kyburz; Olivier Schorr; Renate Gay; Steffen Gay
Journal:  Cell Immunol       Date:  2005-02       Impact factor: 4.868

5.  Flagellin contamination of recombinant heat shock protein 70 is responsible for its activity on T cells.

Authors:  Zhiyong Ye; Yunn-Hwen Gan
Journal:  J Biol Chem       Date:  2006-12-18       Impact factor: 5.157

6.  Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept.

Authors:  Clio P Mavragani; Timothy B Niewold; Niki M Moutsopoulos; Stanley R Pillemer; Sharon M Wahl; Mary K Crow
Journal:  Arthritis Rheum       Date:  2007-12

7.  Osteoclasts are essential for TNF-alpha-mediated joint destruction.

Authors:  Kurt Redlich; Silvia Hayer; Romeo Ricci; Jean-Pierre David; Makiyeh Tohidast-Akrad; George Kollias; Günter Steiner; Josef S Smolen; Erwin F Wagner; Georg Schett
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

8.  Interleukin-1 and tumor necrosis factor activities partially account for calvarial bone resorption induced by local injection of lipopolysaccharide.

Authors:  C Y Chiang; G Kyritsis; D T Graves; S Amar
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

9.  Stimulation by TLR5 modulates osteoclast differentiation through STAT1/IFN-beta.

Authors:  Hyunil Ha; Jong-Ho Lee; Ha-Neui Kim; Han Bok Kwak; Hyun-Man Kim; Shee Eun Lee; Joon Haeng Rhee; Hong-Hee Kim; Zang Hee Lee
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

10.  Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.

Authors:  K Kobayashi; N Takahashi; E Jimi; N Udagawa; M Takami; S Kotake; N Nakagawa; M Kinosaki; K Yamaguchi; N Shima; H Yasuda; T Morinaga; K Higashio; T J Martin; T Suda
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

View more
  30 in total

1.  Osteoimmunology in 2014: Two-faced immunology-from osteogenesis to bone resorption.

Authors:  Hiroshi Takayanagi
Journal:  Nat Rev Rheumatol       Date:  2015-01-06       Impact factor: 20.543

Review 2.  Circulating monocytes: an appropriate model for bone-related study.

Authors:  Y Zhou; H-W Deng; H Shen
Journal:  Osteoporos Int       Date:  2015-07-21       Impact factor: 4.507

3.  Inflammation: A TLR5-TNF positive feedback loop in rheumatoid arthritis.

Authors:  Nicholas J Bernard
Journal:  Nat Rev Rheumatol       Date:  2014-09-23       Impact factor: 20.543

Review 4.  Toll-like receptors and chronic inflammation in rheumatic diseases: new developments.

Authors:  Leo A B Joosten; Shahla Abdollahi-Roodsaz; Charles A Dinarello; Luke O'Neill; Mihai G Netea
Journal:  Nat Rev Rheumatol       Date:  2016-05-12       Impact factor: 20.543

Review 5.  Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis.

Authors:  Kenneth S Rosenthal; Katalin Mikecz; Harold L Steiner; Tibor T Glant; Alison Finnegan; Roy E Carambula; Daniel H Zimmerman
Journal:  Expert Rev Vaccines       Date:  2015-03-18       Impact factor: 5.217

Review 6.  TLRs, future potential therapeutic targets for RA.

Authors:  Hatem A Elshabrawy; Abdul E Essani; Zoltán Szekanecz; David A Fox; Shiva Shahrara
Journal:  Autoimmun Rev       Date:  2016-12-15       Impact factor: 9.754

7.  VLR Recognition of TLR5 Expands the Molecular Characterization of Protein Antigen Binding by Non-Ig-based Antibodies.

Authors:  Robin J Gunn; Brantley R Herrin; Sharmistha Acharya; Max D Cooper; Ian A Wilson
Journal:  J Mol Biol       Date:  2018-03-26       Impact factor: 5.469

8.  Early supplemental α2-macroglobulin attenuates cartilage and bone damage by inhibiting inflammation in collagen II-induced arthritis model.

Authors:  Shengchun Li; Chuan Xiang; Xiaochun Wei; Xiaojuan Sun; Ruifang Li; Pengcui Li; Jian Sun; Dinglu Wei; Yong Chen; Yanxiang Zhang; Lei Wei
Journal:  Int J Rheum Dis       Date:  2019-01-04       Impact factor: 2.454

9.  Identification of a Novel Toll-like Receptor 7 Endogenous Ligand in Rheumatoid Arthritis Synovial Fluid That Can Provoke Arthritic Joint Inflammation.

Authors:  Seung-Jae Kim; Zhenlong Chen; Abdul B Essani; Hatem A Elshabrawy; Michael V Volin; Suncica Volkov; William Swedler; Shiva Arami; Nadera Sweiss; Shiva Shahrara
Journal:  Arthritis Rheumatol       Date:  2016-05       Impact factor: 10.995

Review 10.  Links Between the Microbiome and Bone.

Authors:  Christopher J Hernandez; Jason D Guss; Marysol Luna; Steven R Goldring
Journal:  J Bone Miner Res       Date:  2016-07-26       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.